Bristol-Myers Squibb presents Phase III data demonstrating that investigational all-oral daclatasvir and asunaprevir therapy achieved SVR12 rates of up to 90%
10 April 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced Phase III results from the global HALLMARK-Dual study investigating the all-oral, interferon- and ribavirin-free regimen of daclatasvir...